Cargando…

Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007

BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 regist...

Descripción completa

Detalles Bibliográficos
Autores principales: Khayamzadeh, Maryam, Aliakbari, Fereshte, Zolghadr, Zahra, Emadeddin, Majid, Ahadi, Mahsa, Akbari, MohammadEsmaeil, Abedi, Amir Reza, Nematollahi, Shahrzad, Hosseini, Jalil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691705/
https://www.ncbi.nlm.nih.gov/pubmed/33391383
http://dx.doi.org/10.30699/ijp.2020.118375.2287
_version_ 1783614350630584320
author Khayamzadeh, Maryam
Aliakbari, Fereshte
Zolghadr, Zahra
Emadeddin, Majid
Ahadi, Mahsa
Akbari, MohammadEsmaeil
Abedi, Amir Reza
Nematollahi, Shahrzad
Hosseini, Jalil
author_facet Khayamzadeh, Maryam
Aliakbari, Fereshte
Zolghadr, Zahra
Emadeddin, Majid
Ahadi, Mahsa
Akbari, MohammadEsmaeil
Abedi, Amir Reza
Nematollahi, Shahrzad
Hosseini, Jalil
author_sort Khayamzadeh, Maryam
collection PubMed
description BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. RESULTS AND CONCLUSION: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.
format Online
Article
Text
id pubmed-7691705
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Iranian Society of Pathology
record_format MEDLINE/PubMed
spelling pubmed-76917052021-01-01 Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007 Khayamzadeh, Maryam Aliakbari, Fereshte Zolghadr, Zahra Emadeddin, Majid Ahadi, Mahsa Akbari, MohammadEsmaeil Abedi, Amir Reza Nematollahi, Shahrzad Hosseini, Jalil Iran J Pathol Short Communication BACKGROUND & OBJECTIVE: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran. METHODS: Information on 3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole. RESULTS AND CONCLUSION: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted. Iranian Society of Pathology 2021 2020-10-10 /pmc/articles/PMC7691705/ /pubmed/33391383 http://dx.doi.org/10.30699/ijp.2020.118375.2287 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Khayamzadeh, Maryam
Aliakbari, Fereshte
Zolghadr, Zahra
Emadeddin, Majid
Ahadi, Mahsa
Akbari, MohammadEsmaeil
Abedi, Amir Reza
Nematollahi, Shahrzad
Hosseini, Jalil
Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title_full Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title_fullStr Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title_full_unstemmed Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title_short Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007
title_sort five-year survival rate of bladder cancer in iran during 2001-2007
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691705/
https://www.ncbi.nlm.nih.gov/pubmed/33391383
http://dx.doi.org/10.30699/ijp.2020.118375.2287
work_keys_str_mv AT khayamzadehmaryam fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT aliakbarifereshte fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT zolghadrzahra fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT emadeddinmajid fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT ahadimahsa fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT akbarimohammadesmaeil fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT abediamirreza fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT nematollahishahrzad fiveyearsurvivalrateofbladdercanceriniranduring20012007
AT hosseinijalil fiveyearsurvivalrateofbladdercanceriniranduring20012007